US FDA accepts and grants priority review status to AstraZeneca’s sNDA for Calquence to treat patients with untreated MCL: Cambridge, UK Friday, October 4, 2024, 09:00 Hrs [IST] ...
On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing ...
Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...
Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...
AstraZeneca's supplemental New Drug Application for Calquence (acalabrutinib) has been granted Priority Review by the US FDA ...
AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously ...
Diagnosed with leukaemia nearly three decades ago, The Alarm's Mike Peters is now hopeful of "a way to be cured once and for ...
Mike Peters, frontman of Welsh band The Alarm, is in remission from an aggressive cancer after taking part in an experimental ...
Peters, who has supported U2 and Status Quo on tour, was first diagnosed with chronic lymphocytic leukaemia (CLL) more than ...
The lead singer of rock band The Alarm is in remission from an aggressive cancer thanks to an NHS drug trial. Mike Peters had ...
There, he agreed to take part in a randomised phase II clinical trial investigating the combination of a targeted therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback